Eurocine Vaccines is publically listed at
Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.
To be notified with news,
sign up to our newsfeed =>
Legal Advisor is
Lindahl and MCL.
Sedermera is our Financial Advisor.
Patent and Intellectual Property (IP) advisors are
Zacco and AWA.
Preferential Share Issue
Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of shares up to cirka 9,7 MSEK before issue costs, which subscription period begins Wednesday 2 August 2023.
(in Swedish) Eurocine Vaccines´ Memorandum 2023
(Tilläggsmemorandum, in Swedish) Supplementary Memorandum 7 August 2023 Extraordinary General Meeting
26 July 2023
Below follow documents related to the Extraordinary General Meeting on the 26 July 2023:
Notice (Kallelse, in Swedish)
Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)
Proxy Form (Fullmaktsformulär, in Swedish)
Latest Investor Presentation
CEO Dr. Hans Arwidsson presents at Aktieportföljen Live, 11 October 2022
Future Financial Reports
The Interim Report July – December 2023 is planned to be available 28 February 2024.
Existing Financial Reports
Interim Report July – September 2023
Annual Report 2022 – 2023 (Swedish)
Full Year Report July 2022 – June 2023
Interim Report July 2022 – March 2023
Interim Report July – December 2022
Interim Report July – September 2022
Full Year Report July 2021 – June 2022 =>
Interim Report July 2021 – March 2022 =>
Annual Review 2021 =>
Interim Report July – December 2021 =>
Interim Report July – September 2021 =>
Full Year Report July 2020 – June 2021 =>
Interim Report July 2020 – March 2021 =>
Half Year Report July – December 2020 =>
Interim Report July – September 2020 =>